Clinical trials
Drug Resistance, Bacterial clinical trials
Below are recruiting drug resistance, bacterial clinical trials, each written for real people, not researchers. We’re tracking 21 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06258551Recruiting
Tracking hard-to-treat bacteria in ICU and transplant patients
This study will track how certain hard-to-treat bacteria spread and cause infections in people who are in the intensive care unit (ICU) or have had a stem cell transplant. The goal is to better understand and prevent these infections in vulnerable patients.
Houston, TexasAges 18 years+ - NCT07094984Recruiting
Clearing resistant gut bacteria: three FMT methods
This trial tests three different ways to clear antibiotic-resistant bacteria from your gut using fecal microbiota transplant (FMT). It may help if you have a confirmed resistant infection and are looking for a treatment to reduce the risk of future infections.
WarsawAges 18 years+ - NCT05561504Recruiting
Study of stomach bacteria resistance in adults
This study looks at how common a stomach bacteria infection is and which antibiotics still work. You may help researchers by providing consent for related study participation and sample tracking.
MunichAges 18 years+ - NCT06451172RecruitingEarly Phase 1
New antibiotic eye drops for drug-resistant eye infections
This trial tests a new type of antibiotic eye drop for people with serious eye infections that don't respond to standard antibiotics. It aims to see if these drops can safely treat the infection and help improve vision.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07052604Recruiting
Antibiotic treatment for a rare pneumonia in ICU patients
This study looks at how well antibiotics work for pneumonia caused by a specific bacterium (Stenotrophomonas maltophilia) in patients who are on breathing machines in the intensive care unit (ICU). It will help doctors choose the best treatment.
Saint-Denis, FranceAges 18 years+ - NCT05835206RecruitingPhase 2
Drug to reduce antibiotic-resistant gut bacteria
This Phase 2 study tests whether an investigational treatment can help clear or reduce antibiotic-resistant bacteria living in the gut. It may help prevent these germs from causing future infections by targeting specific resistant bacteria found on stool or rectal swabs.
Atlanta, GeorgiaAges 18 years+ - NCT04172025Recruiting
Swiss database for tracking hard-to-treat infections
This study builds a Swiss database using lab genetic testing (whole genome sequencing) plus basic patient information to track outbreaks of serious, drug-resistant, and sometimes high-infectious pathogens. Your data could help researchers understand how these germs spread and how to better prevent them.
BaselAges Any age - NCT05947656Recruiting
NaviFUS treatment for drug-resistant temporal lobe seizures
This trial tests the NaviFUS system to treat seizures that keep happening despite seizure medicines, specifically in people with temporal lobe epilepsy. If you qualify, you would be carefully checked before and during the study, including seizure tracking and brain scans, to see whether treatment helps reduce seizures.
Melbourne, VictoriaAges 18 years+ - NCT06738771Recruiting
Antibiotic treatment for tough Pseudomonas infections
This study tests a specific antibiotic plan for adults with a hard-to-treat Pseudomonas infection that needs IV medicine. It aims to find the best way to treat these serious infections.
AmiensAges 18 years+ - NCT07206745Recruiting
Chinese and Western medicine for severe pneumonia from drug-resistant bacteria
This trial tests a combination of traditional Chinese and Western medicine for adults with severe pneumonia caused by bacteria that are resistant to multiple antibiotics. It aims to see if this combined approach can improve treatment outcomes.
Zhengzhou, HenanAges 18–80 - NCT03671967RecruitingPhase 4
Compare two antibiotics for hard-to-treat E. coli and Klebsiella bloodstream infections
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
Calgary, AlbertaAges 18 years+ - NCT06321536RecruitingPhase 2
Testing microbiota therapy for resistant bacteria in the gut
This study tests a treatment made from healthy donor stool (called microbiota therapy) given as an enema or through a feeding tube. It aims to help people who carry resistant bacteria that are hard to treat, by reducing or clearing those bacteria from the gut.
Atlanta, GeorgiaAges 18 years+ - NCT04188743RecruitingPhase 2/Phase 3
Stool transplant to clear antibiotic-resistant gut germs
This trial tests whether a stool (fecal) transplant from a screened donor can help remove antibiotic-resistant gut bacteria (MDRO) that keep coming back in your stool tests. It aims to reduce colonization that makes follow-up and treatment harder.
Ghent, Oost-VlaanderenAges 18 years+ - NCT07071103RecruitingPhase 2
Low-dose radiation and immunotherapy for resistant solid tumors
This trial tests a combination of low-dose radiation to the intestines and immunotherapy for people whose cancer has stopped responding to standard treatments including immunotherapy. It may offer a new option when other therapies have failed.
Shantou, GuangdongAges 18–80 - NCT07326540RecruitingPhase 3
Testing a new antibiotic for drug-resistant pneumonia in the hospital
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
TbilisiAges 18–82 - NCT07089186RecruitingPhase 3
Study of meropenem and pralurbactam for certain antibiotic-resistant infections
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
ShanghaiAges 18–80 - NCT06616597RecruitingPhase 2
Targeting gut bacteria to help prostate cancer treatment work again
This trial tests whether adding metronidazole, an antibiotic, can make abiraterone work better in men with metastatic prostate cancer whose PSA is rising despite treatment. It aims to target gut bacteria that may be fueling resistance to the therapy.
Baltimore, MarylandAges 18 years+ - NCT07470853RecruitingPhase 1
Study of HWK-016 for advanced ovarian or endometrial cancer
This trial tests a new drug called HWK-016, which is designed to target and deliver medicine directly to cancer cells that have a specific marker (MUC16). It is for people with advanced ovarian or endometrial cancer to see if it can shrink tumors or slow their growth.
Little Rock, ArkansasAges 18 years+ - NCT07339267RecruitingPhase 1
Safety and dosing study of ASP5541 in Chinese men with metastatic prostate cancer
This study tests a new drug called ASP5541 for Chinese men with prostate cancer that has spread. The drug is given as a shot, and researchers want to see if it is safe and what the right dose might be.
Beijing, Beijing MunicipalityAges 18–85 - NCT07723248RecruitingPhase 3
Oral Rinzimetostat for Advanced Prostate Cancer After Abiraterone
This study tests an experimental pill called rinzimetostat (ORIC-944) for men with advanced prostate cancer that has spread and stopped responding to abiraterone. It may offer a new option if you have not had many other treatments yet.
Charlotte, North CarolinaAges 18 years+ - NCT07444814RecruitingPhase 1
HWK-007 for advanced solid tumors
This trial tests a new drug called HWK-007, which is designed to target and attack cancer cells while sparing healthy ones. It is for people with specific advanced solid tumors (lung, endometrial, or ovarian cancer) that have not responded well to standard treatments.
Little Rock, ArkansasAges 18 years+
Hear when a new Drug Resistance, Bacterial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for drug resistance, bacterial?
- Yes. Clin2 currently lists 21 recruiting drug resistance, bacterial studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a drug resistance, bacterial trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a drug resistance, bacterial trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.